Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes

Abstract

Teneligliptin 20 mg is well tolerated, safe, and significantly improves glycemic control in diabetic patients with end-stage renal disease. Teneligliptin 20 mg once daily was considered to be more potent than voglibose 0.2 mg t.i.d. or vildagliptin 50 mg qd.

Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes

“…Teneligliptin, a novel peptidomimetic-chemotype prolylthiazolidine-based DPP-4 inhibitor, was approved for clinical use in 2013 in Japan [16]. The addition of teneligliptin has been reported to be effective, safe, and generally well tolerated in various types of Japanese patients with T2DM [17][18][19][20]. This study aimed to evaluate the cardio-protective effects of teneligliptin treatment in T2DM patients with a high risk of chronic heart failure.…”

Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies

“…Thus, these results indicate that, although caution is required, dose adjustments may not be necessary in patients with impaired renal or hepatic function. Furthermore, teneligliptin at a dose of 20 mg appeared to be well tolerated, and to significantly improve glycemic control in diabetic patients with end-stage renal disease [23]. Because renal disease is a common complication in patients with T2DM, it will be necessary to continuously collect information regarding safety in patients with renal dysfunction.…”

Teneligliptin: Heralding Change in Type 2 Diabetes

“…Significant decrease in HbA1c & glucose levels was observed in hemodialysis patients after Teneligliptin treatment. Otsuki H et al [51] studied effect of Teneligliptin on 14 hemodialysis patients. 7 (Newly started), 4 (switched from Voglibose 0.2 mg TID) and 3 (switched from Vildagliptin 50 mg OD) patients were treated with Teneligliptin 20 mg OD for a duration of 28 weeks.…”